Summary
Chapters
Video Info
Kate Fleetwood follows six volunteers as they participate in a phase II clinical trial for glial-cell derived neurotrophic factor (GDNF), as a treatment for Parkinson's disease.
-
Chapter 1: Introductory Sequences for The Parkinson's Drug Trial: A Miracle Cure? Episode 1
icon angle down -
Chapter 2: Introduction to the Phase II GDNF Clinical Trial
icon angle down -
Chapter 3: Ron Johnson and Tom Isaacs, Trial Volunteers, Share Their Reasons for Participating in the Phase II GDNF Clinical Trial
icon angle down -
Chapter 4: How GDNF Works and Results From the Phase I GDNF Clinical Trials
icon angle down -
Chapter 5: Selecting Volunteers for the Phase II GDNF Clinical Trial
icon angle down -
Chapter 6: Volunteers in the Phase II GDNF Clinical Trial Prepare for Their Surgeries
icon angle down -
Chapter 7: Professor Stephen Gill Explains the Brain Surgery Required for the Phase II GDNF Clinical Trial
icon angle down -
Chapter 8: Volunteers in the Phase II GDNF Clinical Trial Share Their Post-Procedure Experiences
icon angle down -
Chapter 9: Infusions Begin in the Phase IIGDNF Clinical Trial
icon angle down -
Chapter 10: After 15 Months, Adverse Effects Temporarily Halt the Phase IIGDNF Clinical Trial
icon angle down -
Chapter 11: After an Eight-Month Hiatus, the Phase II GDNF Clinical Trial Resumes
icon angle down -
Chapter 12: Closing Comments and Credits for The Parkinson's Drug Trial: A Miracle Cure? Episode 1
icon angle down